OA12506A - Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. - Google Patents

Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. Download PDF

Info

Publication number
OA12506A
OA12506A OA1200300273A OA1200300273A OA12506A OA 12506 A OA12506 A OA 12506A OA 1200300273 A OA1200300273 A OA 1200300273A OA 1200300273 A OA1200300273 A OA 1200300273A OA 12506 A OA12506 A OA 12506A
Authority
OA
OAPI
Prior art keywords
mct
cells
compound
acid
bone marrow
Prior art date
Application number
OA1200300273A
Other languages
English (en)
Inventor
Jean Barabe
Lyne Gagnon
Pierre Laurin
Christopher Penney
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of OA12506A publication Critical patent/OA12506A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/003—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with alcohols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA1200300273A 2001-04-18 2002-04-18 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. OA12506A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28445801P 2001-04-18 2001-04-18

Publications (1)

Publication Number Publication Date
OA12506A true OA12506A (en) 2006-05-29

Family

ID=23090294

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300273A OA12506A (en) 2001-04-18 2002-04-18 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors.

Country Status (30)

Country Link
US (2) US7745488B2 (cs)
EP (2) EP1900364B1 (cs)
JP (3) JP5026655B2 (cs)
KR (1) KR20030096323A (cs)
CN (1) CN1633286A (cs)
AP (1) AP1740A (cs)
AU (2) AU2002308456B2 (cs)
BG (1) BG66418B1 (cs)
BR (1) BR0208984A (cs)
CA (2) CA2444463C (cs)
CY (1) CY1107081T1 (cs)
CZ (1) CZ305273B6 (cs)
DE (1) DE60223670T2 (cs)
DK (2) DK1900364T3 (cs)
EA (1) EA007322B1 (cs)
EE (1) EE200300510A (cs)
ES (2) ES2295397T3 (cs)
HU (1) HUP0303817A3 (cs)
IL (3) IL158322A0 (cs)
MX (1) MXPA03009436A (cs)
NO (1) NO335105B1 (cs)
NZ (2) NZ541140A (cs)
OA (1) OA12506A (cs)
PL (2) PL223348B1 (cs)
PT (2) PT1900364E (cs)
SI (1) SI1385498T1 (cs)
SK (1) SK12772003A3 (cs)
TN (1) TNSN03089A1 (cs)
WO (1) WO2002083120A2 (cs)
ZA (1) ZA200307778B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305273B6 (cs) * 2001-04-18 2015-07-15 Prometic Biosciences Inc. Mastné kyseliny jako faktory aktivace a přežití neutrofilů
MXPA05008382A (es) * 2003-02-07 2005-11-04 Prometic Biosciences Inc Acidos grasos, gliceridos y analogos con longitud de cadena media como estimuladores de eritropoyesis.
CN1839111B (zh) 2003-07-25 2010-04-21 普罗米蒂克生物科学公司 中链脂肪酸金属盐的制备方法
EP1742663A2 (en) * 2004-04-15 2007-01-17 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MX2007002727A (es) * 2004-09-03 2008-03-04 Prometic Biosciences Inc Derivados de purinilo sustituidos con actividad inmunomoduladora y quimioprotectora, y su uso solos o con acidos grasos de longitud de cadena media o gliceridos.
ES2376201T3 (es) * 2004-10-01 2012-03-09 Prometic Biosciences Inc. Alcoholes grasos de longitud de cadena media como estimuladores de la hematopoyesis.
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
CA2599291C (en) * 2005-02-28 2013-12-31 Alphabeta Ab Compounds for reducing aggregation of amyloid beta-peptide
EP3001902A1 (en) * 2006-05-17 2016-04-06 Cognate Therapeutics, Inc. Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
EP2180787B1 (en) 2007-08-01 2013-10-30 University of Pittsburgh - Of the Commonwealth System of Higher Education Nitro oleic acid modulation of type ii diabetes
AU2008318196B2 (en) * 2007-11-02 2014-04-10 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
PT2231166E (pt) * 2007-12-19 2013-06-17 Prometic Biosciences Inc Ácidos gordos com comprimento de cadeia média, sais e riglicéridos em combinação com gemcitabina para tratamento do cancro pancreático
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CN102099024B (zh) * 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
CA2963659C (en) 2008-09-17 2020-06-23 Chiasma Inc. Use of oral octreotride compositions
EP2165713B1 (en) * 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
US9066902B2 (en) 2009-07-31 2015-06-30 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
MX370567B (es) * 2012-05-09 2019-12-17 Cantex Pharmaceuticals Inc Tratamiento de mielosupresion.
US20160199338A1 (en) 2013-08-19 2016-07-14 Enzychem Lifesciences Corporation Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis
ES2752179T3 (es) * 2014-05-15 2020-04-03 Enzychem Lifesciences Corp Métodos para tratar neutropenia
FI3253401T3 (fi) 2015-02-03 2025-07-09 Amryt Endo Inc Akromegallian hoitaminen suun kautta annettavalla oktreotidilla
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
SG10201913953UA (en) 2015-10-02 2020-03-30 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
CA3021660A1 (en) 2016-04-22 2017-10-26 Receptor Life Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
SG11201810580PA (en) 2016-06-08 2018-12-28 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN107382710B (zh) * 2017-08-19 2020-11-06 中国铁道科学研究院集团有限公司铁道建筑研究所 一种接枝抗氧剂分子的多元醇
EA202090566A1 (ru) * 2017-09-12 2020-07-14 Санреджен Хэлскэр Аг Липиды, содержащие нечетное количество атомов углерода, и их применение в качестве фармацевтической композиции или питательной добавки
AR113750A1 (es) * 2017-10-05 2020-06-10 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad
EP3672610A4 (en) * 2017-10-05 2021-06-02 Receptor Holdings, Inc. FAST-ON AND EXTENDED EFFECTS OF HERBAL AND SYNTHETIC CANNABINOID FORMULATIONS
KR102054401B1 (ko) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제
EP3801526B1 (en) 2018-05-25 2023-12-27 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
KR102831968B1 (ko) 2018-08-31 2025-07-08 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
MX2021003750A (es) 2018-10-11 2021-06-15 Basf As Compuestos aromaticos y usos farmaceuticos de los mismos.
WO2020106767A1 (en) 2018-11-19 2020-05-28 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
JP7735864B2 (ja) * 2019-10-31 2025-09-09 日本ゼオン株式会社 電気化学素子用機能層およびその製造方法、電気化学素子用機能層付きセパレータおよびその製造方法、並びに電気化学素子およびその製造方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2023067501A1 (en) * 2021-10-18 2023-04-27 Enzychem Lifesciences Corporation Compositions and methods for treating mucositis
EP4511349A1 (en) * 2022-04-21 2025-02-26 Merck Sharp & Dohme LLC Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4703062A (en) * 1984-01-16 1987-10-27 Baxter Travenol Laboratories, Inc. Parenteral nutrition with medium and long chain triglycerides
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US6060459A (en) * 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH02134326A (ja) * 1988-11-14 1990-05-23 Snow Brand Milk Prod Co Ltd 高度侵襲用経腸栄養剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0526630A4 (en) * 1991-02-22 1993-08-11 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
JP3132085B2 (ja) * 1991-09-06 2001-02-05 ウェルファイド株式会社 脂肪乳剤
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
DE19648566A1 (de) * 1995-11-28 1997-06-05 Braun Melsungen Ag Hydrolyseoptimierte Lipidemulsionen und ihre Verwendung
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) * 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
US6017531A (en) * 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
AU9221698A (en) 1997-09-04 1999-03-22 Biozone Laboratories, Inc. Oral liposomal delivery system
BR9814693B1 (pt) * 1997-11-19 2011-04-19 suspensões de polìmero fluidificado de polissacarìdeos catiÈnicos em emolientes e processo para preparação de uma composição para cuidado pessoal.
DE69833333T2 (de) 1997-11-20 2006-10-19 Jhon, Gil Ja Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2003513019A (ja) * 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス，インコーポレイテッド トコール可溶性治療剤の組成物
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1289530B1 (en) * 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
ATE284687T1 (de) * 2000-06-20 2005-01-15 Nutrition Sciences Mittelkettige fettsäuren und deren verwendung als antimikrobielles mittel
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
CZ305273B6 (cs) * 2001-04-18 2015-07-15 Prometic Biosciences Inc. Mastné kyseliny jako faktory aktivace a přežití neutrofilů
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
MXPA05008382A (es) * 2003-02-07 2005-11-04 Prometic Biosciences Inc Acidos grasos, gliceridos y analogos con longitud de cadena media como estimuladores de eritropoyesis.
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
CN1839111B (zh) 2003-07-25 2010-04-21 普罗米蒂克生物科学公司 中链脂肪酸金属盐的制备方法
MX2007002727A (es) * 2004-09-03 2008-03-04 Prometic Biosciences Inc Derivados de purinilo sustituidos con actividad inmunomoduladora y quimioprotectora, y su uso solos o con acidos grasos de longitud de cadena media o gliceridos.
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
PL366435A1 (en) 2005-01-24
EA007322B1 (ru) 2006-08-25
CZ305273B6 (cs) 2015-07-15
US20040147599A1 (en) 2004-07-29
DE60223670D1 (de) 2008-01-03
NO20034644L (no) 2003-11-25
PT1900364E (pt) 2013-12-19
CA2763637C (en) 2016-08-23
CA2763637A1 (en) 2002-10-24
IL158322A (en) 2011-09-27
EE200300510A (et) 2004-02-16
CN1633286A (zh) 2005-06-29
ES2295397T3 (es) 2008-04-16
CA2444463A1 (en) 2002-10-24
EP1385498A2 (en) 2004-02-04
AU2006201163A1 (en) 2006-04-13
NZ541140A (en) 2006-11-30
EP1900364A2 (en) 2008-03-19
JP5026655B2 (ja) 2012-09-12
JP2010053135A (ja) 2010-03-11
JP6420089B2 (ja) 2018-11-07
KR20030096323A (ko) 2003-12-24
CZ20032685A3 (cs) 2004-06-16
TNSN03089A1 (en) 2005-12-23
DK1900364T3 (da) 2014-01-13
ES2439738T3 (es) 2014-01-24
US8487001B2 (en) 2013-07-16
CY1107081T1 (el) 2012-10-24
AP1740A (en) 2007-05-10
PL222876B1 (pl) 2016-09-30
MXPA03009436A (es) 2004-12-06
PL402948A1 (pl) 2013-05-13
NO20034644D0 (no) 2003-10-17
NZ528690A (en) 2005-08-26
SK12772003A3 (sk) 2004-07-07
AU2002308456B2 (en) 2005-12-22
EP1900364A3 (en) 2009-09-23
AU2006201163B2 (en) 2006-10-05
ZA200307778B (en) 2004-04-21
BR0208984A (pt) 2004-06-29
DE60223670T2 (de) 2008-03-06
AP2003002888A0 (en) 2003-12-31
EP1385498B1 (en) 2007-11-21
JP2004525957A (ja) 2004-08-26
DK1385498T3 (da) 2008-03-25
HUP0303817A3 (en) 2009-10-28
EP1900364B1 (en) 2013-09-25
IL195200A (en) 2011-11-30
PT1385498E (pt) 2007-12-14
SI1385498T1 (sl) 2008-04-30
US7745488B2 (en) 2010-06-29
EA200301131A1 (ru) 2004-04-29
IL195200A0 (en) 2009-08-03
BG108280A (bg) 2004-09-30
PL223348B1 (pl) 2016-10-31
BG66418B1 (bg) 2014-03-31
CA2444463C (en) 2012-03-20
WO2002083120A2 (en) 2002-10-24
JP5657879B2 (ja) 2015-01-21
JP2014231519A (ja) 2014-12-11
WO2002083120A3 (en) 2003-05-22
US20100279959A1 (en) 2010-11-04
HUP0303817A2 (hu) 2004-03-01
IL158322A0 (en) 2004-05-12
NO335105B1 (no) 2014-09-15

Similar Documents

Publication Publication Date Title
OA12506A (en) Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors.
AU2002308456A1 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN102816189B (zh) α-半乳糖神经酰胺衍生物、其药物可接受的盐、制备方法和含有其作为活性成分的用于免疫佐剂的药物组合物
WO2008139261A2 (en) Omega-3 lipid compound
TW202432119A (zh) 作為sting促效劑之雜環化合物
JP5504891B2 (ja) 新規擬似糖脂質及びその用途
EP1976505A1 (en) Combretastatin derivatives and related therapeutic methods
JP2008531675A (ja) 必須多価不飽和脂肪酸の環式グリセリドを使用するサイトカイン調節物質
KR20040071138A (ko) 이중 에스테르류